This trial is designed to try two new cancer drugs together for the first time. The
investigators think that they might be effective in some types of bowel cancer. The first
part of the trial will see what doses of the two drugs can safely be given together. Once the
investigators have identified a suitable dose combination they will look at how effective
treatment is in bowel cancers where either the RAS gene is mutated, or MET is over-active. In
the trial the investigators will look at samples of blood, skin and tumour to check the drugs
are working in the way expected. The trial will take place in three sites in the UK and 5
sites in Europe. The trial is funded as part of the European commission's FP7 program.
Phase:
Phase 1
Details
Lead Sponsor:
University of Oxford
Collaborators:
Array BioPharma Beaumont Hospital Belfast Health and Social Care Trust Covance European Commission European Georges Pompidou Hospital Hopital St Antoine, Paris Hospital Vall d'Hebron Oxford University Hospitals NHS Trust Pfizer Q2 solutions QPS Holdings Queen's University, Belfast Saint Antoine University Hospital University Hospital, Antwerp University of Paris 5 - Rene Descartes University of Turin, Italy Velindre NHS Trust